Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 8/20 | 0.48 |
| ▸ | CTSK | P43235 | 8/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390418 | 0.84 | KMT2A (0.56) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL31517881 | 0.84 | KMT2A (0.56) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL3010367 | 0.84 | KMT2A (0.56) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL13612429 | 0.83 | CTSK (0.68) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL25413150 | 0.83 | KMT2A (0.55) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL1022916 | 0.83 | KMT2A (0.55) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL29918018 | 0.83 | KMT2A (0.55) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL25413155 | 0.83 | KMT2A (0.55) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL6295388 | 0.83 | KMT2A (0.55) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL18653900 | 0.83 | KMT2A (0.55) | KMT2ACTSSCTSKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-8993607-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2012-02-23 | — | — | US | disclosed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | KMT2A 1103/4885CTSS 1227/4885CTSK 957/4885 |
| US-20120046234-A1 | THERAPEUTIC COMPOUNDS | MKI67, MCL1, TP53 | KMT2A 3148/4885CTSS 1323/4885CTSK 1336/4885 |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | SRR, EPHX2, ALOX5 | KMT2A 4634/4885CTSS 3591/4885CTSK 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.